Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Immunovant, Inc. (IMVT) And Encourages Investors to Reach Out
Friday, 25 September 2026 01:00 PM
Class Action
NEW YORK CITY, NY / ACCESS Newswire / September 25, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Immunovant, Inc. ("Immunovant" or "the Company") (NASDAQ:IMVT). Investors who purchased Immunovant securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/immunovant-inc-imvt-class_action_lawsuit.

Immunovant Investigation Details
On September 23, 2026, Immunovant announced that its proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus did not achieve statistical significance on its primary endpoint. The company said it plans to stop developing the drug for that indication. Following the announcement, Immunovant 's stock price dropped 7.37% on September 23, 2026.
What's Next for Immunovant Investors?
If you are aware of any facts relating to this investigation or purchased Immunovant securities, you can assist this investigation by visiting the firm's site: bgandg.com/cases/immunovant-inc-imvt-class_action_lawsuit. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Immunovant Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Immunovant Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE: Bronstein, Gewirtz & Grossman, LLC